Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tissue Adhesions Clear all
Completed Phase 1Phase 2 Interventional

Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the Hand

NCT00261209
View directory record Official record
Conditions
Adhesion of Flexor Tendon of Hand
Interventions
Collagenase, Collagenase injection
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Sep 2, 2026, 1:57 PM EDT
Completed No phase listed Observational

Comparative Effectiveness Multicenter Trial for Adhesion Characteristics of Ventral Hernia Repair Mesh

NCT01355939
View directory record Official record
Conditions
Ventral Hernia, Adhesions
Interventions
Clinically-Indicated Abdominal Re-Exploration Surgery
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
6
States / cities
Phoenix, Arizona • San Diego, California • Springfield, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System

NCT00650442
View directory record Official record
Conditions
Healthy
Interventions
Estradiol Transdermal System Placebo - Alternate Adhesive, Estradiol Transdermal System Placebo - Current Adhesive
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 66 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Sep 2, 2026, 1:57 PM EDT
Suspended Phase 3 Interventional

Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery

NCT00865488
View directory record Official record
Conditions
Ovarian Cysts, Endometriosis, Adhesions
Interventions
ADHEXIL
Biological
Lead sponsor
OMRIX Biopharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2009 · Synced Sep 2, 2026, 1:57 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy

NCT01632202
View directory record Official record
Conditions
Intrauterine Adhesions
Interventions
Seprafilm, Sterile Saline Solution
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)

NCT01077921
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Laura M. De Castro, MD
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 4 Interventional

SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery

NCT00531739
View directory record Official record
Conditions
Adhesions, Colectomy
Interventions
Polylactic Acid Sheet
Other
Lead sponsor
Cytori Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Sep 2, 2026, 1:57 PM EDT
Not listed Not applicable Interventional

Fascial Scar Mobilization Techniques in Treating Chronic Caesarian Section Scar Pain

NCT02836626
View directory record Official record
Conditions
Cesarean Section, Cicatrix, Tissue Adhesions
Interventions
deep fascial mobilization, superficial fascial mobilization
Procedure
Lead sponsor
Rocky Mountain University of Health Professions
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Manchester, New Hampshire • McLean, Virginia • Lynnwood, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 2, 2026, 1:57 PM EDT
Terminated Phase 1 Interventional

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

NCT02346955
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer
Interventions
CM-24 (MK-6018), Pembrolizumab (MK-3475)
Biological
Lead sponsor
Famewave Ltd.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 1 Interventional

Bone Marrow Transplant With Abatacept for Non-Malignant Diseases

NCT01917708
View directory record Official record
Conditions
Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Shwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia, Thalassemia Major, Hemophagocytic Lymphohistiocytosis, Sickle Cell Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 2, 2026, 1:57 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cranberry Juice and Cardiovascular Disease

NCT01295684
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Cranberry juice, Placebo
Other
Lead sponsor
United States Department of Agriculture (USDA)
Federal
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2011 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Not applicable Interventional

An Evaluation of the Effect of the AmnioFix Amniotic Membrane Allograft in Patients Undergoing Posterior Instrumentation Removal

NCT01357187
View directory record Official record
Conditions
Adhesions of Soft Tissue
Interventions
Scheduled removal of posterior instrumentation with AmnioFix, Scheduled removal of posterior instrumentation without AmnioFix
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Juveena™ Hydrogel System Following Transcervical Gynecologic Procedures (TCGP) At High-Risk for Intrauterine Adhesions

NCT05394662
View directory record Official record
Conditions
Intrauterine Adhesion
Interventions
Juveena Hydrogel System, Transcervical Gynecologic Procedures (TCGP)
Device · Procedure
Lead sponsor
Rejoni Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 2, 2026, 1:57 PM EDT
Not listed Phase 2 Interventional

Pediatric Multicenter Study of REPEL-CV

NCT00116233
View directory record Official record
Conditions
Adhesions
Interventions
REPEL-CV
Device
Lead sponsor
SyntheMed
Industry
Eligibility
1 Day to 1 Year
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Little Silver, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 27, 2005 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection

NCT02836470
View directory record Official record
Conditions
Ileus, Post-Operative Adhesions
Interventions
LB1148, Placebo
Drug
Lead sponsor
Palisade Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Mobile, Alabama • Yuma, Arizona • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 2, 2026, 1:57 PM EDT
Terminated Not applicable Interventional Results available

A Trial to Reduce Adhesions Following a Primary Cesarean Section

NCT01819467
View directory record Official record
Conditions
Tissue Adhesions
Interventions
Seprafilm
Device
Lead sponsor
South East Area Health Education Center, Wilmington, NC
Other
Eligibility
12 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 2, 2026, 1:57 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

a Study to Evaluate Adhesion Risk in Fertility Patients' Status Post Laparoscopic Myomectomy.

NCT01971060
View directory record Official record
Conditions
Uterine Fibroids, Infertility
Interventions
surgery utilizing V-Loc suture
Device
Lead sponsor
The Advanced Gynecologic Surgery Institute
Other
Eligibility
18 Years to 42 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery

NCT01330433
View directory record Official record
Conditions
Congenital Heart Defect, Surgery-Induced Tissue Adhesions, Hemorrhage
Interventions
CoSeal Surgical Spray Group
Device
Lead sponsor
Loma Linda University
Other
Eligibility
Up to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 2, 2026, 1:57 PM EDT
Withdrawn Not applicable Interventional

An Adhesion Reduction Plan in the Management of the Surgical Open Abdomen

NCT01010464
View directory record Official record
Conditions
Open Abdomen
Interventions
Adhesion Reduction Plan
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced Sep 2, 2026, 1:57 PM EDT
Completed No phase listed Observational

PMCF Study for COSEAL® in Gynecologic Surgery

NCT05996809
View directory record Official record
Conditions
Adhesion
Interventions
Coseal
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 2, 2026, 1:57 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

NCT04152863
View directory record Official record
Conditions
Advanced/Metastatic Melanoma
Interventions
Gebasaxturev IV, Gebasaxturev ITu, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Detroit, Michigan • New Brunswick, New Jersey • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure

NCT04784728
View directory record Official record
Conditions
Healthy
Interventions
Lidocaine topical system 1.8%
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 2, 2026, 1:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Composition of Dental Plaque

NCT00001726
View directory record Official record
Conditions
Dental Caries, Dental Plaque, Periodontal Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 1:57 PM EDT